The long-term trend of the EPS is a vital number as it helps understand the future potential of Apellis Pharmaceuticals. I will do my best to analyze this stock, but there is limited information, therefore please check back later by doing a search here or going to the tag page for the stock symbol APLS here. Growth in EPS is an important measure of administration performance because it shows how much money Apellis Pharmaceuticals is making for it’s investors or shareholders.
Apellis Pharmaceuticals trades as part of the healthcare sector and biotechnology industry. The company CEO is Cedric Francois. Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.
Previous Intraday Performance:
The APLS shares had a previous change of 1.39% which opened at 15.21 and closed at 15.34. It moved to an intraday high of 15.47 and a low of 14.73.
SeekingAlpha: Midday Gainers / Losers (10/18/2018)
Historical Performance:
Over the last five trading days, APLS shares returned -6.63% and in the past 30 trading days it returned 14.18%. Over three months, it changed -16.63%. In one year it has changed 12.38% and within that year its 52-week high was 32.00 and its 52-week low was 11.45. APLS stock is 33.97% above its 52 Week Low.
Our calculations result in a 200 day moving average of 19.54 and a 50 day moving average of 15.52. Right now, APLS stock is trading -21.51% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
SeekingAlpha: Apellis Pharma down 17% on hiccup in late-stage study of APL-2
Liquidity:
The company has a market cap of $861.8m with 56.2m shares outstanding and a float of 52.8m shares. Trading volume was 141,303 shares and has experienced an average volume of 279,360 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Apellis Pharmaceuticals was -4.23 which ended on 31st of December 2017. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.63.
Below was the last reported quarterly earnings per share:
09-30-2018: -0.64
06-30-2018: -0.61
03-31-2018: -0.43
12-31-2017: -0.60
Indicators Also to Watch:
Based on the latest filings, there is 6.00% of insider ownership and 51.20% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.
I calculated the beta to be 0.00
SeekingAlpha: Apellis Pharma down 17% on hiccup in late-stage study of APL-2
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -226.87%, return on assets is -84.63% and price-to-book is 4.50.
Company Score Card:
Results are out of six:
0 : Growth Expectations Result
5 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result
Related Tags: Apellis Pharmaceuticals, APLS, Biotechnology, Healthcare
